Humalog is a short-acting insulin that helps control blood sugar levels in those with diabetes type 1 or type 2. This new generic Humalog will be considered an “authorized generic,” which is slightly different from the term, “generic drug”, you may be used to hearing.
Here’s what you need to know.
What is an authorized generic?
An authorized generic is an exact copy of its brand-name counterpart. It even comes from the same manufacturer as the brand-name drug (or another manufacturer that’s approved by the brand manufacturer). The only differences between an authorized generic and its brand-name version are their packaging and price points.
In contrast, a generic drug is similar to its brand-name counterpart with some differences in inactive ingredients. What’s more, generic drugs typically have multiple manufacturers, which allows market competition to bring down their price points.
In the case of Humalog, Lilly is the manufacturer for both the brand and authorized generic versions of the drug, meaning they will make a profit from sales of both generic insulin lispro and Humalog.
How will generic Humalog be sold?
This new, authorized generic will be sold under the name, insulin lispro, through an Eli Lilly subsidiary called ImClone Systems.
Like Humalog, generic insulin lispro will be available in a single vial and a box of five kwikpens. According to Eli Lilly, the new generic will be made available as soon as possible.
How much will generic Humalog cost?
Eli Lilly plans to price Humalog’s authorized generic at half the current price of Humalog. This means the list prices for insulin lispro will be $137.35 for one vial and $265.20 for one pack of five kwikpens. 50% is an improvement in price, yes, but at well over $100 per vial, this life-saving drug could still be unaffordable for many.
Source: Read Full Article